Transcranial Magnetic Stimulation for Opiate Dependence

(VICTORY Trial)

This trial aims to determine whether stimulating a specific brain area with repetitive Transcranial Magnetic Stimulation (rTMS) can reduce cravings and opioid use in individuals with opiate dependence. Participants will undergo brain stimulation sessions, and some may opt for brain imaging to observe its effects on the brain. Ideal candidates are those who began taking buprenorphine for opioid use disorder within the past year and have experienced a return to opioid use during that period. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to new treatment options for opioid dependence.

The trial protocol does not specify if you must stop taking your current medications. However, a doctor will review your medications to decide if you can participate, considering your medical history and any recent changes in your medication.

Research has shown that repetitive transcranial magnetic stimulation (rTMS) is generally safe and easy to manage. In previous studies, most participants experienced only minor side effects, such as a mild headache or slight pain during or after treatment. These symptoms typically resolve on their own or can be managed with over-the-counter pain medication.

Most treatments for opiate dependence, like methadone or buprenorphine, work by replacing or reducing opioid use through chemical means. But Repetitive Transcranial Magnetic Stimulation (rTMS) works differently, targeting brain activity with magnetic pulses. This technique is non-invasive and drug-free, focusing on stimulating specific parts of the brain, potentially reducing cravings and withdrawal symptoms. Researchers are excited because rTMS offers a new avenue that might help those who haven't had success with traditional medication therapies. Plus, it could lead to fewer side effects compared to current drug-based treatments.

Research has shown that repetitive Transcranial Magnetic Stimulation (rTMS) can help reduce cravings for opioids. In this trial, participants will receive either active rTMS or a sham treatment. One study demonstrated that a session of rTMS targeting a brain area involved in decision-making decreased these cravings. Additional research suggests that rTMS might benefit people with opioid use disorder by reducing cravings triggered by specific cues. These findings indicate that rTMS could be a promising tool for managing opioid dependence by influencing brain areas related to cravings.³⁵⁶⁷⁸